Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 14, 2009. The filing discloses changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation:
- Base Salary: $330,000 annually for the new CFO.
- Performance Bonus: Targeted at 30% of base salary.
- Equity Award: 200,000 stock options vesting annually over four years.
Material Changes
The primary material change is the restructuring of the finance leadership team effective August 14, 2009:
- Resignation: Christopher C. Camut resigned as Chief Financial Officer.
- Internal Promotion: Mr. Camut assumed the new role of Vice President, Government Contracting and Special Projects.
- Appointment: Charles A. Reinhart III was appointed Senior Vice President and Chief Financial Officer. He joined the company on August 10, 2009, and assumed the CFO role on August 14, 2009.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the company's business outlook. The document focuses solely on the personnel transition and the new CFO's background, which includes prior roles at Millennium Pharmaceuticals and Cephalon, Inc.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Confirm the effective dates of the CFO transition (August 14, 2009) and the new executive's start date (August 10, 2009).
- Review the terms of the 200,000 stock option grant and the vesting schedule starting August 10, 2010.
- Check subsequent filings for any financial impact of the leadership change or updates on government contracting initiatives.